These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38909246)

  • 1. An international survey assessing the effects of the duration of attack-free period on health-related quality of life for patients with hereditary angioedema.
    Itzler R; Lumry WR; Sears J; Braverman J; Li Y; Brennan CJ; Koch GG
    Orphanet J Rare Dis; 2024 Jun; 19(1):241. PubMed ID: 38909246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study.
    Lumry WR; Zuraw B; Cicardi M; Craig T; Anderson J; Banerji A; Bernstein JA; Caballero T; Farkas H; Gower RG; Keith PK; Levy DS; Li HH; Magerl M; Manning M; Riedl MA; Lawo JP; Prusty S; Machnig T; Longhurst H;
    Orphanet J Rare Dis; 2021 Feb; 16(1):86. PubMed ID: 33588897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of lanadelumab on attack frequency and QoL in Japanese patients with hereditary angioedema: Report of five cases.
    Hioki C; Oda Y; Moriwaki S; Fukunaga A
    J Dermatol; 2024 Jun; 51(6):873-877. PubMed ID: 38268496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.
    Johnson F; Stenzl A; Hofauer B; Heppt H; Ebert EV; Wollenberg B; Lochbaum R; Hahn J; Greve J; Trainotti S
    Clin Rev Allergy Immunol; 2023 Dec; 65(3):354-364. PubMed ID: 37914894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and burden of illness in patients with hereditary angioedema: findings from a multinational patient survey.
    Mendivil J; Murphy R; de la Cruz M; Janssen E; Boysen HB; Jain G; Aygören-Pürsün E; Hirji I; Devercelli G
    Orphanet J Rare Dis; 2021 Feb; 16(1):94. PubMed ID: 33602292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for the long-term prevention of hereditary angioedema attacks.
    Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the cost and quality-of-life impact of on-demand-only medications for adults with hereditary angioedema.
    Castaldo AJ; Jervelund C; Corcoran D; Boysen HB; Christiansen SC; Zuraw BL
    Allergy Asthma Proc; 2021 Mar; 42(2):108-117. PubMed ID: 33581742
    [No Abstract]   [Full Text] [Related]  

  • 8. The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center.
    Buttgereit T; Vera Ayala C; Aykanat S; Weller K; Gutsche A; Maurer M; Magerl M
    Front Immunol; 2024; 15():1405317. PubMed ID: 38799421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
    Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
    Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.
    Lumry WR; Craig T; Zuraw B; Longhurst H; Baker J; Li HH; Bernstein JA; Anderson J; Riedl MA; Manning ME; Keith PK; Levy DS; Caballero T; Banerji A; Gower RG; Farkas H; Lawo JP; Pragst I; Machnig T; Watson DJ
    J Allergy Clin Immunol Pract; 2018; 6(5):1733-1741.e3. PubMed ID: 29391286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study.
    Lumry WR; Weller K; Magerl M; Banerji A; Longhurst HJ; Riedl MA; Lewis HB; Lu P; Devercelli G; Jain G; Maurer M;
    Allergy; 2021 Apr; 76(4):1188-1198. PubMed ID: 33258114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.
    Zanichelli A; Azin GM; Cristina F; Vacchini R; Caballero T
    Orphanet J Rare Dis; 2018 Apr; 13(1):51. PubMed ID: 29631595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Content validation and psychometric evaluation of the Angioedema Quality of Life Questionnaire for hereditary angioedema.
    Vanya M; Watt M; Shahraz S; Kosmas CE; Rhoten S; Costa-Cabral S; Mendivil J; Devercelli G; Weller K
    J Patient Rep Outcomes; 2023 Apr; 7(1):33. PubMed ID: 37012445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life and its risk factors in Chinese hereditary angioedema patients.
    Liu S; Wang X; Xu Y; Xu Q; Zhi Y
    Orphanet J Rare Dis; 2019 Aug; 14(1):191. PubMed ID: 31395105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical manifestations, diagnosis, and treatment of hereditary angioedema: survey data from 94 physicians in Japan.
    Ohsawa I; Honda D; Nagamachi S; Hisada A; Shimamoto M; Inoshita H; Mano S; Tomino Y
    Ann Allergy Asthma Immunol; 2015 Jun; 114(6):492-8. PubMed ID: 25872948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema.
    Lumry WR; Maurer M; Weller K; Riedl MA; Watt M; Yu M; Devercelli G; Meunier J; Banerji A;
    Ann Allergy Asthma Immunol; 2023 Jul; 131(1):101-108.e3. PubMed ID: 37028510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States.
    Banerji A; Davis KH; Brown TM; Hollis K; Hunter SM; Long J; Jain G; Devercelli G
    Ann Allergy Asthma Immunol; 2020 Jun; 124(6):600-607. PubMed ID: 32169514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.
    Srinivasan C; Ritchie B; Adatia A
    Front Immunol; 2024; 15():1339421. PubMed ID: 38318176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL.
    Prior N; Remor E; Pérez-Fernández E; Caminoa M; Gómez-Traseira C; Gayá F; Aabom A; Aberer W; Betschel S; Boccon-Gibod I; Bouillet L; Bygum A; Csuka D; Farkas H; Gomide M; Grumach A; Leibovich I; Malbran A; Moldovan D; Mihaly E; Obtulowicz K; Perpén C; Peveling-Oberhag A; Porebski G; Chavannes CR; Reshef A; Staubach P; Wiednig M; Caballero T
    J Allergy Clin Immunol Pract; 2016; 4(3):464-473.e4. PubMed ID: 26969268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic Treatment in Hereditary Angioedema Is Associated with Reduced Anxiety in Patients in Leipzig, Germany.
    Zarnowski J; Rabe M; Kage P; Simon JC; Treudler R
    Int Arch Allergy Immunol; 2021; 182(9):819-826. PubMed ID: 33887730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.